Short DAPT Eligibility Calculator
Clinical decision support
Assess bleeding and ischemic risk after PCI
For adults with acute coronary syndrome treated with PCI and a contemporary drug-eluting stent. Select all findings that apply, based on documented clinical assessment.
Antiplatelet review
Clinical context
This qualitative tool supports review of DAPT duration after ACS and PCI. It does not calculate a validated numerical score and does not independently establish eligibility for single antiplatelet therapy.
How to interpret the assessment
- For ACS patients who are not at high bleeding risk, the default strategy is DAPT for at least 12 months.
- For selected ACS patients at high bleeding risk, transition to single antiplatelet therapy after 1 month may be reasonable after individualized assessment.
- In patients who tolerate DAPT with ticagrelor, ticagrelor monotherapy after at least 1 month is a distinct guideline-supported bleeding-reduction strategy.
- For patients requiring long-term oral anticoagulation, use the anticoagulation-specific pathway; aspirin discontinuation 1–4 weeks after PCI with an oral anticoagulant plus a P2Y12 inhibitor is recommended by the 2025 US guideline.
- Complex PCI, recurrent ischemia, stent thrombosis, ventricular dysfunction, planned procedures, and patient-specific factors require clinician review rather than automatic rule-based decisions.
Important limitation
The ischemic features in this tool are qualitative prompts, not a validated score or a complete list of contraindications to abbreviated DAPT. The tool does not replace ARC-HBR assessment, formal risk tools where appropriate, angiographic/procedural review, or shared decision-making.
References
Circulation. 2019;140:240–261. doi:10.1161/CIRCULATIONAHA.119.040167
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.